Barclays PLC Halozyme Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 305,939 shares of HALO stock, worth $14.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

305,939

Previous 305,939 -0.0%

Holding current value

$14.5 Million

Previous $17.5 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$51.3 - $64.42 $7.82 Million - $9.82 Million	152,474 Added 99.35%	305,939 $17.5 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $4.96 Million - $6.87 Million	-131,114 Reduced 46.07%	153,465 $8.04 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $4.25 Million - $5.29 Million	-126,119 Reduced 30.71%	284,579 $11.6 Million
Q4 2023 Feb 15, 2024	BUY	$33.32 - $42.1 $6.54 Million - $8.27 Million	196,346 Added 91.6%	410,698 $15.2 Million
Q3 2023 Nov 07, 2023	SELL	$36.46 - $44.03 $2.42 Million - $2.93 Million	-66,470 Reduced 23.67%	214,352 $8.19 Million
Q2 2023 Aug 03, 2023	BUY	$30.28 - $38.74 $2.61 Million - $3.34 Million	86,194 Added 44.29%	280,822 $10.1 Million
Q1 2023 May 04, 2023	BUY	$32.86 - $55.7 $2.56 Million - $4.34 Million	77,974 Added 66.84%	194,628 $7.43 Million
Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $211,036 - $313,129	5,268 Added 4.73%	116,654 $6.64 Million
Q3 2022 Nov 03, 2022	BUY	$38.53 - $51.78 $2.88 Million - $3.88 Million	74,875 Added 205.08%	111,386 $4.4 Million
Q2 2022 Aug 12, 2022	SELL	$37.35 - $48.3 $1.42 Million - $1.83 Million	-37,937 Reduced 50.96%	36,511 $1.61 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $4.46 Million - $5.72 Million	-139,429 Reduced 65.19%	74,448 $2.97 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $2.53 Million - $3.24 Million	79,476 Added 59.13%	213,877 $8.6 Million
Q3 2021 Nov 09, 2021	BUY	$38.47 - $46.42 $233,243 - $281,444	6,063 Added 4.72%	134,401 $5.47 Million
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $4.34 Million - $5.74 Million	-111,805 Reduced 46.56%	128,338 $5.83 Million
Q1 2021 May 13, 2021	BUY	$39.51 - $51.45 $2.45 Million - $3.19 Million	62,071 Added 34.86%	240,143 $10 Million
Q4 2020 Feb 11, 2021	SELL	$25.81 - $43.62 $1.47 Million - $2.48 Million	-56,965 Reduced 24.24%	178,072 $7.61 Million
Q3 2020 Nov 12, 2020	BUY	$25.74 - $29.63 $291,196 - $335,204	11,313 Added 5.06%	235,037 $6.18 Million
Q2 2020 Aug 12, 2020	BUY	$16.25 - $26.81 $1.06 Million - $1.75 Million	65,239 Added 41.16%	223,724 $6 Million
Q1 2020 May 13, 2020	SELL	$13.9 - $21.83 $354,658 - $556,992	-25,515 Reduced 13.87%	158,485 $2.85 Million
Q4 2019 Feb 10, 2020	BUY	$14.93 - $19.53 $1.25 Million - $1.63 Million	83,622 Added 83.31%	184,000 $3.26 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $100,472 - $116,930	-6,610 Reduced 6.18%	100,378 $1.56 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $130,419 - $152,612	8,842 Added 9.01%	106,988 $1.84 Million
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $737,802 - $930,456	52,927 Added 117.05%	98,146 $1.58 Million
Q4 2018 Feb 14, 2019	SELL	$13.33 - $18.66 $972,983 - $1.36 Million	-72,992 Reduced 61.75%	45,219 $662,000
Q3 2018 Nov 14, 2018	BUY	$16.68 - $18.41 $1.64 Million - $1.81 Million	98,175 Added 489.99%	118,211 $2.15 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $588,577 - $708,246	-34,889 Reduced 63.52%	20,036 $337,000
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $144,634 - $179,733	-8,478 Reduced 13.37%	54,925 $1.08 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $395,501 - $491,129	23,612 Added 59.34%	63,403 $1.29 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $467,942 - $692,363	39,791	39,791 $692,000

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account